English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective— Integrins are attractive therapeutic targets. Inhibition of integrin αIIb β3 effectively blocks platelet aggregation. However, limitations with intravenous αIIb β3 antagonists and failure of oral αIIb β3 antagonists prompted doubts on the current concept of ligand-mimetic integrin blockade.Methods and Results— Evaluating P-selectin expression on platelets by flow cytometry, we report a mechanism of paradoxical platelet activation by ligand-mimetic αIIb β3 antagonists and define three requirements: (1) Induction of ligand-bound conformation of αIIb β3 , (2) receptor clustering, (3) prestimulation of platelets. Conformational change is inducible by clinically used ligand-mimetic αIIb β3 antagonists, RGD-peptides, and anti-LIBS antibodies. In a mechanistic experimental model, clustering is achieved by crosslinking integrins via antibodies, and preactivation is induced by low-dose ADP. Finally, we demonstrate that platelet adhesion on collagen represents an in vivo correlate of platelet prestimulation and receptor clustering, in which the presence of ligand-mimetic αIIb β3 antagonists results in platelet activation as detected by P-selectin, CD63, and CD40L expression as well as by measuring Ca2+ -signaling. Blockade of the ADP receptor P2Y12 by AR-C69931MX and clopidogrel inhibits αIIb β3 antagonist-induced platelet activation.Conclusion— These findings can explain limitations of ligand-mimetic anti-αIIb β3 therapy. They describe potential benefits of concomitant ADP receptor blockade and support a shift in drug development from ligand-mimetic toward allosteric or activation-specific integrin antagonists.

A Mechanistic Model for Paradoxical Platelet Activation by Ligand-Mimetic αIIbβ3(GPIIb/IIIa) Antagonists

A Mechanistic Model for Paradoxical Platelet Activation by Ligand-Mimetic α_IIbβ₃(GPIIb/IIIa) Antagonists